



Contact:  
Bill Enright  
President & CEO  
Phone: 240-654-1450  
Email: [enright@vaxin.com](mailto:enright@vaxin.com)

**FOR IMMEDIATE RELEASE**

**VAXIN APPOINTS BRIGADIER GENERAL (RET.) KLAUS SCHAFER  
TO BOARD OF DIRECTORS**

**Gaithersburg, MD – July 10, 2012** – Vaxin Inc., a clinical stage vaccine development company today announced that Brigadier General (ret.) Klaus O. Schafer, MD, MPH has been appointed to its Board of Directors. General Schafer has an esteemed military career in medicine, significant programmatic and management experience in biodefense initiatives and in depth knowledge of leading and managing early stage biotechnology companies.

“We are very pleased to have someone with Klaus’s knowledge, leadership and background in biodefense initiatives join our Board,” said David J. Drutz, MD, Vaxin’s Chairman. “Biodefense initiatives are an important component of Vaxin’s current portfolio and Klaus’s military experience, knowledge of infectious diseases and private sector leadership skills are tremendous assets that will be invaluable as we continue to advance our NasoVAX influenza and AdVAV anthrax vaccine candidates and position them for commercial success.”

General Schafer has over 30 years of leadership experience, having held senior positions in both government and industry. His experiences include senior level strategy and programmatic management of DoD’s \$1 billion annual chemical and biological defense program as the Deputy Assistant to the Secretary of Defense for chem/bio defense. He retired from the Air Force as the Assistant Surgeon General responsible for medical readiness and after establishing the Science and Technology Office. His private sector activities include Vice President of Business Development for Compressus Inc., a telemedicine start up and most recently as CEO and cofounder of TessArae LLC, a biotech genetic testing diagnostics company. Today he is President & CEO of Touchstone Associates LLC, his private consulting firm, helping small to medium sized businesses navigate government opportunities.

Dr. Schafer is a graduate of the U.S. Air Force Academy. He received his Medical Degree from the University of Iowa School of Medicine in 1977; a Master of Public Health degree in 1984 from the University of Texas School of Health Science; and is a graduate of the Industrial College of the Armed Forces, 1994, earning a Master of Science Degree.

## **About Vaxin:**

Vaxin Inc. is a clinical stage company, developing next generation vaccines to address significant public health and biodefense needs. Vaxin is focused on vaccines designed to protect people against influenza and anthrax infection using proprietary, patented technologies for intranasal delivery, and is also developing unique animal health vaccines including an *in ovo* vaccines for preventing influenza outbreaks in poultry populations and a vaccine to sterilize dogs and cats. Vaxin's vaccines are designed to provide a safe, effective, easily administered, rapidly manufactured, and cost-competitive alternative to currently marketed products. Vaxin's intranasally delivered, adenovirus-based vaccines have successfully completed pre-clinical development, Investigational New Drug (IND) review and Phase 1 clinical studies of NasoVAX for seasonal and pre-pandemic influenza indications, demonstrating both proof-of-concept in man and providing an initial safety assessment of the technology platform. The proposed vectored anthrax vaccine product, AdVAV, is identical in route of administration, structure and manufacturing to these influenza candidates with the exception of the encoded antigen (*Bacillus anthracis* PA rather than *influenza virus* HA). It is expected that a nasal anthrax vaccine would greatly boost vaccine coverage against a bioterrorist attack during a crisis, and significantly reduce adverse side effects when compared to those induced by systemically-delivered anthrax vaccines. Vaxin recently received a multi-million dollar BARDA contract to advance this vaccine through Phase 1 clinical studies should the contract option be exercised.

## **Forward-looking statements:**

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

# # #